Progression and Incidence of Myopia Among Schoolchildren in the Post-COVID-19 Pandemic Period: a Prospective Cohort Study in Shantou, China
Overview
Affiliations
Objectives: To determine the progression and incidence of myopia in Chinese schoolchildren in the post-COVID-19 pandemic period in Shantou, China.
Design: Prospective cohort study.
Setting: Shantou Myopia Study, China.
Participants: 1-year follow-up data were available for 621 881 schoolchildren (301 999 females). Data on spherical equivalent refraction (SER) were collected.
Primary And Secondary Outcome Measures: The primary outcomes were myopia progression and incidence. Myopia progression is defined as a change of SER towards the negative direction in the follow-up visit. Incidence is defined as the proportion of schoolchildren who were not myopic but developed myopia in the follow-up study. Age, sex and SER at baseline were evaluated as associated factors for myopia burden, which were defined as the secondary outcomes.
Results: Mean progression of SER was -0.35±0.97 D for the population (ranging from -0.06 D at 18 years of age to -0.46 D at 11 years of age), with a rapid myopic progression for students at the age of 10-12 years (-0.50 D in girls and -0.44 D in boys). A myopic shift greater than -0.50 D/year occurred in 256 299 eyes (41.21%). Myopic progression in refraction was associated with the 10-12 years age groups (OR 1.42; 95% CI 1.39 to 1.45, p<0.001), female sex (OR 1.09; 95% CI 1.08 to 1.10, p<0.001) and higher refractive errors at baseline (OR>1.00, p<0.001). The annual incidence of myopia among schoolchildren was 24.85%, with an incidence of 26.69% in girls and 23.02% in boys.
Conclusions: Our study revealed an annual myopia progression of -0.35 D and an incidence of 24.85% among schoolchildren in the post-COVID-19 pandemic period. Myopia progressed rapidly at 10-12 years of age, with -0.50 D in girls and -0.44 D in boys. The incidence was higher for children aged 10-11 years and for girls.
Mu J, Zhong H, Jiang M, Yang W Front Med (Lausanne). 2024; 11:1368219.
PMID: 39281822 PMC: 11392885. DOI: 10.3389/fmed.2024.1368219.